1. Private Equity (PE)/Venture Capital (VC) investments in pharmaceutical companies have grown by more than 3.5 times in 2020 and for the first time crossed $1 billion to touch $1.69 billion during January to September 2020.

2. Fund managers said investors remained positive on the pharma manufacturing activity in India, which further strengthened during the Covid-19 period, on account of restrictions imposed on pharma imports from China.
3. During January to September 2020, the sector attracted $1.69 billion (in 19 deals) as compared to $368 million, a year ago. 
4. 2020 is a year in which healthcare & life sciences has taken centrestage due to the coronavirus (Covid-19) pandemic.
5. Valuations in this segment are seen to be quite resilient even during the present crisis. This segment presently trades at the 10-year median value in terms of both EBITDA and revenue multiples. 
Source: Business Standard


Leave a Reply

Your email address will not be published.